|
US2009087450A1
|
|
Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
|
|
US2007212338A1
|
|
Hybrid cells
|
|
AU2006302587A1
|
|
Latent procytotoxins and uses thereof
|
|
AU2006201184A1
|
|
Hybrid cells
|
|
WO2004091551A2
|
|
Anti-tumor vasculature effects of human serum albumin derivatives
|
|
CN1787838A
|
|
Antitumor agents comprising a targeting portion and an immune response triggering portion
|
|
CA2500397A1
|
|
Aav itr-mediated modulation
|
|
AU2003220685A8
|
|
Metastasis modulating activity of highly sulfated oligosaccharides
|
|
JP2004002276A
|
|
Human prolactin antagonist-vascularization inhibitor fusion protein
|
|
AU2002329858A1
|
|
Gpi-anchored cytokines
|
|
AU2002350085A1
|
|
Membrane associated progesterone receptor
|
|
CA2411244A1
|
|
Therapeutic pore-forming peptides
|
|
CA2404088A1
|
|
Bi-functional cancer treatment agents
|
|
EP1541675A2
|
|
Hybrid cells obtainable from antigen presenting cells
|
|
AU3644301A
|
|
Hybrid cells obtainable from antigen presenting cells
|
|
AU4308699A
|
|
Use of anti-prolactin agents to treat proliferative conditions
|
|
EP1079851A1
|
|
Use of anti-prolactin agents to treat cancer
|
|
AU7981098A
|
|
Wheelchair adaptor for locomotion on ice
|
